RecruitingPHASE1, PHASE2NCT03686124
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Immatics US, Inc.
- Principal Investigator
- Cedrik Britten, M.D., M.DImmatics US, Inc.
- Intervention
- IMA203 Product(biological)
- Enrollment
- 375 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2032
Study locations (18)
- Stanford Cancer Institute, Stanford, California, United States
- University of Miami Hospital and Clinics, Miami, Florida, United States
- University of Chicago Medical Center, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus, Ohio, United States
- University of Pennsylvania, Perelamn Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Baden-Wurttemberg, Germany
- Klinikum rechts der Isar der Technischen Universität München, Munich, Bavaria, Germany
- Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
- Universitätsklinikum Bonn - Medizinische Klinik III, Bonn, North Rhine-Westphalia, Germany
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Rhineland-Palatinate, Germany
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03686124 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center